Association of a reduction in low-density lipoprotein cholesterol with incident cardiovascular and cerebrovascular events among people with type 2 diabetes mellitus

European Journal of Preventive Cardiology

Volumn 21, Issue 7, 2014, Pages 855-865

  Li, Lin ^a   Ambegaonkar, Baishali M ^b   Reckless, John Pd ^c   Jick, Susan ^a  

^a BOSTON UNIVERSITY   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c ROYAL UNITED HOSPITALS BATH NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

cardiovascular events; cerebrovascular events; Low density lipoprotein cholesterol; type 2 diabetes mellitus

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; TRIACYLGLYCEROL;

ADULT; AGED; ALCOHOL ABUSE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL VASCULAR DISEASE; PRESCRIPTION; PRIORITY JOURNAL; SMOKING; AGE; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; DOSE RESPONSE; INCIDENCE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK REDUCTION; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; RISK FACTOR; STROKE; UNITED KINGDOM;

ADULT; AGED; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GREAT BRITAIN; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE;

EID: 84885656443     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/2047487313481752     Document Type: Article

References (19)

1. Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease: A statement for healthcare professionals from the American Heart Association. Circulation. 1999 ; 100: 1134-1146
2. Betteridge DJ. Diabetic dyslipidaemia. Eur J Clin Invest. 1999 ; 29: S12 - S16
3. Haffner SM, Mykkänen L, Stern MP, et al. Greater effect of diabetes on LDL size in women than in men. Diabetes Care. 1994 ; 17: 1164-1171
4. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
5. Lewis SJ. Lipid-lowering therapy: Who can benefit?. Vasc Health Risk Manag. 2011 ; 7: 525-534
6. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005 ; 366: 1267-1278
7. Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: A meta-analysis. Lancet. 2008 ; 371: 117-125
8. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet. 2004 ; 364: 685-696
9. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. Brit Med J. 1991 ; 302: 766-768
10. Jick H, Terris BZ, Derby LE, et al. Further validation of information recorded on a general practitioner based computerized data resource in the United Kingdom. Pharmacoepidemiol Drug Saf. 1992 ; 1: 347-349
11. Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al. Validity of the general practice research database. Pharmacotherapy. 2003 ; 23: 686-689
12. Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the General Practice Research Database: A systematic review. Br J Gen Pract. 2010 ; 60: e128 - e136
13. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet. 2003 ; 361: 2005-2016
14. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994 ; 344: 1383-1389
15. Shepherd J, Cobbe SM, Ford I, Isles CG, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995 ; 333: 1301-1307
16. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after MI in patients with average cholesterol levels. N Engl J Med. 1996 ; 335: 1001-1009
17. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet. 2002 ; 360: 7-22
18. Cheung BM. Statins for people with diabetes. Lancet. 2008 ; 371: 94-95
19. Eriksson M, Zethelius B, Eeg-Olofsson K, et al. Blood lipids in 75,048 type 2 diabetic patients: A population-based survey from the Swedish National diabetes register. Eur J Cardiovasc Prev Rehabil. 2011 ; 18: 97-105